JP2007202515A - アンジオテンシンi変換酵素活性の測定方法 - Google Patents
アンジオテンシンi変換酵素活性の測定方法 Download PDFInfo
- Publication number
- JP2007202515A JP2007202515A JP2006027503A JP2006027503A JP2007202515A JP 2007202515 A JP2007202515 A JP 2007202515A JP 2006027503 A JP2006027503 A JP 2006027503A JP 2006027503 A JP2006027503 A JP 2006027503A JP 2007202515 A JP2007202515 A JP 2007202515A
- Authority
- JP
- Japan
- Prior art keywords
- ace
- dehydrogenase
- angiotensin
- compound
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 230000000694 effects Effects 0.000 title claims abstract description 34
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 title claims abstract description 15
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 80
- 239000000758 substrate Substances 0.000 claims abstract description 49
- 101710088194 Dehydrogenase Proteins 0.000 claims abstract description 48
- ULGJWNIHLSLQPZ-UHFFFAOYSA-N 7-[(6,8-dichloro-1,2,3,4-tetrahydroacridin-9-yl)amino]-n-[2-(1h-indol-3-yl)ethyl]heptanamide Chemical compound C1CCCC2=NC3=CC(Cl)=CC(Cl)=C3C(NCCCCCCC(=O)NCCC=3C4=CC=CC=C4NC=3)=C21 ULGJWNIHLSLQPZ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 108010003977 aminoacylase I Proteins 0.000 claims abstract description 28
- 230000009471 action Effects 0.000 claims abstract description 12
- 150000008575 L-amino acids Chemical class 0.000 claims abstract description 9
- 230000001590 oxidative effect Effects 0.000 claims abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 5
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 claims description 107
- 238000012360 testing method Methods 0.000 claims description 29
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 6
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000005515 coenzyme Substances 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 51
- 238000006243 chemical reaction Methods 0.000 description 48
- 230000035484 reaction time Effects 0.000 description 26
- 108010078975 3-hydroxybutyrylglycyl-glycyl-glycine Proteins 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 238000005259 measurement Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000000354 decomposition reaction Methods 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000005541 ACE inhibitor Substances 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 6
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 6
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical compound C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 229960000830 captopril Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 4
- 239000002220 antihypertensive agent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 3
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 3
- 102000034279 3-hydroxybutyrate dehydrogenases Human genes 0.000 description 3
- 108090000124 3-hydroxybutyrate dehydrogenases Proteins 0.000 description 3
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 3
- 102000005862 Angiotensin II Human genes 0.000 description 3
- 101800000733 Angiotensin-2 Proteins 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- 229950007884 alacepril Drugs 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229950006323 angiotensin ii Drugs 0.000 description 3
- 229940030600 antihypertensive agent Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000007357 dehydrogenase reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000001008 quinone-imine dye Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- AAXWBCKQYLBQKY-IRXDYDNUSA-N (2s)-2-[[(2s)-2-[(2-benzamidoacetyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)C=1C=CC=CC=1)C1=CN=CN1 AAXWBCKQYLBQKY-IRXDYDNUSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 101710090711 D-beta-hydroxybutyrate dehydrogenase Proteins 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000004186 food analysis Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108010016268 hippuryl-histidyl-leucine Proteins 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940116298 l- malic acid Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- ZMHLUFWWWPBTIU-UHFFFAOYSA-N p-hydroxyhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=C(O)C=C1 ZMHLUFWWWPBTIU-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000000899 pressurised-fluid extraction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
川岸舜朗 編著,「生化学実験法38 食品中の生体機能調節物質研究法」,学会出版センター,「III−3 アンジオテンシン変換酵素阻害物質」,第116〜129頁(1996年発行) D.Y.Cushman,H.S.Cheung,バイオケミカル・ファーマコロジー(Biochem.Pharmacol.),第20巻,第1637〜1648頁(1971年) Y.Kasahara,Y.Ashihara,クリニカル・ケミストリー,第27巻11号,第1922〜1925頁(1981年)
デヒドロゲナーゼの基質化合物に下記ペプチド鎖がアミド結合した化合物(以下、「ACE基質化合物」という)、被検試料、ACEおよびアミノアシラーゼを含む溶液を所定時間反応させる工程、および
を含むことを特徴とする。
デヒドロゲナーゼの基質化合物に下記ペプチド鎖がアミド結合した化合物(ACE基質化合物)、被検試料、ACEおよびアミノアシラーゼを含む溶液を所定時間反応させる工程(以下、「ACE反応工程」という)、および
を含むことを特徴とする。先ず、ACE反応工程について説明する。
ACEによりD−3−ヒドロキシ酪酸−Gly−Gly−Gly(以下、「D−3−ヒドロキシ酪酸」を「3HB」と、「Gly」を「G」という場合がある)が、3HB−GとGly−Glyに切断されていることを確認するために、3HB−GGGとACEの反応の進行により生成するアミノ基の濃度を測定した。3.4mg/mLの3HB−GGG溶液(125μL)へ、超純水(15μL)と0.1U/mLのACE(50μL)を加えて20秒間攪拌し、37℃で0〜120分間反応させた。反応の停止は、1N塩酸(25μL)を加えることにより行なった。なお、反応混合液における3HB−GGGの終濃度は7.35mMであった。反応後、反応溶液をセントリカット(クラボー社製、W−10)に移し、5000rpmで10分間遠心分離して限外濾過することによって、分子量10,000以上の化合物を除いた。
次に、3HB−Gがアミノアシラーゼに切断されて3HB(3−ヒドロキシ酪酸)とGlyが生じることを確認した。先ず、上記実施例1と同様の条件で120分間反応を行なった。次いで、0〜344000U/mLのアミノアシラーゼを加え、0〜30分間反応させた。反応の停止は、1N塩酸(25μL)を加えることにより行なった。
上記実施例1と2の結果をふまえて、3HB−GGGを基質化合物として、ACEとアミノアシラーゼにより3HBまで分解する反応を行なうに当たり、ACEの濃度を0〜0.5U/mLに変化させて、ACE濃度と反応時間の適値を検討した。具体的には、超純水(125μL)への3HB−GGG溶液(7.11mM)、ACE(0〜0.5U/mL)およびアミノアシラーゼ(172000U/mL)を溶解して37℃で反応させ、0〜120分間に20分毎に試料を採取し、実施例2と同様の方法で生成した3HBの濃度を測定した。反応時間と生成した3HB濃度との関係を図3に、反応時間を60分間とした場合におけるACE濃度と3HB濃度との関係を図4に示す。
上記実施例1〜3の結果をふまえ、代表的なACE阻害剤であるカプトプリルとアラセプリルの存在下、ACE活性の測定を行なった。具体的には、0〜1μMのカプトプリルまたは0〜0.1mMのアラセプリル、7.11mMの3HB−GGG、0.2U/mLのACEおよび372000U/mLのアミノアシラーゼからなる反応混合液を調製し、30分間反応を行なった。1N塩酸(25μL)を加えて反応を停止させた後、実施例2と同様の方法により生成した3HBの量を測定した。各ACE阻害剤が存在しない場合に対する阻害率として、カプトプリルの結果を図5に、アラセプリルの結果を図6に示す。
Claims (6)
- デヒドロゲナーゼとして、補酵素であるNADを必要とするデヒドロゲナーゼを用い、酸化化合物の生成量を、NADHの生成量として間接的に測定する請求項1または2に記載のアンジオテンシンI変換酵素活性の測定方法。
- 172000U/mL以上のアミノアシラーゼを用いる請求項1〜4のいずれかに記載のアンジオテンシンI変換酵素活性の測定方法。
- 0.1〜0.25U/mLのアンジオテンシンI変換酵素を用いる請求項1〜5のいずれかに記載のアンジオテンシンI変換酵素活性の測定方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006027503A JP4974329B2 (ja) | 2006-02-03 | 2006-02-03 | アンジオテンシンi変換酵素活性の測定方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006027503A JP4974329B2 (ja) | 2006-02-03 | 2006-02-03 | アンジオテンシンi変換酵素活性の測定方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007202515A true JP2007202515A (ja) | 2007-08-16 |
JP4974329B2 JP4974329B2 (ja) | 2012-07-11 |
Family
ID=38482544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006027503A Active JP4974329B2 (ja) | 2006-02-03 | 2006-02-03 | アンジオテンシンi変換酵素活性の測定方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4974329B2 (ja) |
-
2006
- 2006-02-03 JP JP2006027503A patent/JP4974329B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP4974329B2 (ja) | 2012-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101948906B (zh) | 含有蛋白酶反应促进剂和/或色素稳定剂的试剂 | |
US8241864B2 (en) | Method for determining ACE2 activity | |
JP5129572B2 (ja) | 生体試料中の2項目の測定対象物の同時分別定量方法 | |
JP3159451B2 (ja) | 糖化タンパク質の測定 | |
EP1743034B1 (fr) | Substrats peptidiques reconnus par la toxine botulique de type a, bont/a et leurs utilisations | |
JP6913956B2 (ja) | L−キヌレニンの測定方法及び測定キット | |
JP4974329B2 (ja) | アンジオテンシンi変換酵素活性の測定方法 | |
JP5858945B2 (ja) | 酵素を用いた測定方法 | |
WO2012168470A1 (en) | Method for the determination of the concentration of vitamin b6 in a sample | |
JP4098475B2 (ja) | ビタミンb6についての均一系酵素アッセイおよびh2s検出における改良 | |
Wroczyński et al. | Aromatic aldehydes as fluorogenic indicators for human aldehyde dehydrogenases and oxidases: substrate and isozyme specificityPresented as a poster at the VIIIth International Symposium on Luminescence Spectrometry in Biomedical Analysis, Las Palmas de Gran Canaria, Spain, May 1998. | |
JP4861005B2 (ja) | リパーゼ活性測定用組成物および活性測定法 | |
JP4691627B2 (ja) | 非特異的発色の抑制方法 | |
Isobe et al. | Comparative review of the recent enzymatic methods used for selective assay of L-lysine | |
NL8004080A (nl) | Methode voor het bepalen van transaminases, alsmede een daarmee verband houdende diagnostische uitrusting. | |
NZ330316A (en) | Method and reagent for determining lipase in the presence of an carboxylic acid amide derivative by photometrically determining the amount of dye released from a lipase colour substrate | |
JP2020043857A (ja) | 生体試料中の亜鉛測定試薬及び測定方法 | |
Hawthorne et al. | Evaluation of some fluorogenic substrates for continuous assay of aminopeptidase P | |
FR2807523A1 (fr) | UTILISATION D'UN RESTE PyA-(Z)x-pNF A DES FINS DE DETECTION, IDENTIFICATION ET/OU DOSAGE PAR FLUORESCENCE | |
FR2869908A1 (fr) | Substrat peptidique reconnu par la toxine botulique de type a, bont/a et son utilisation pour detecter et/ou doser ladite toxine ou des inhibiteurs de son activite | |
JP3667470B2 (ja) | 酸性カルボキシペプチダーゼ活性の測定法及び測定試薬 | |
US6696266B1 (en) | Method for assaying ammonia using an NAD-based cycling reaction system | |
JP2663257B2 (ja) | 生体成分測定用試薬の安定化方法 | |
JPH11127894A (ja) | カルボキシペプチダーゼa活性測定方法および測定用キット | |
Holme | Methodological and biological studies of the amino acid oxidases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081212 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110908 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120403 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120409 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4974329 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150420 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |